Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis

Merck & Co. has opened its wallet wide to buy a midphase treatment for life-threatening diseases of the bone marrow, paying $1.35 billion to snap up Imago BioSciences for its oral lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat.